Skip to main content
Erschienen in: Immunologic Research 3/2017

23.11.2016 | Original Article

The role of B7 family costimulatory molecules and indoleamine 2,3-dioxygenase in primary Sjögren’s syndrome and systemic sclerosis

verfasst von: Nóra Legány, László Berta, László Kovács, Attila Balog, Gergely Toldi

Erschienen in: Immunologic Research | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

B7 costimulatory molecules are present on antigen-presenting cells (APCs) and influence intracellular expression of indoleamine 2,3-dioxygenase (IDO), a molecule with important immunoregulatory functions. We determined the frequency of activated (CD11b+) monocytes expressing B7-1, B7-2, B7-H1, and B7-H2 molecules, and that of CD3+ and CD4+ T cells expressing the corresponding CD28, CTLA-4, PD-1, and ICOS receptors in peripheral blood samples of 20 healthy adults and 9 SSc and 15 pSS patients using flow cytometry. We also examined the intracellular expression of IDO. The expression of CD28 was lower in both SSc and pSS patients. The frequency of CTLA-4 was increased in pSS. The expression of ICOS, a stimulator of T cell activation, was elevated in pSS, but not in SSc, while that of its corresponding costimulatory molecule, B7-H2, was strongly decreased in SSc compared to controls. The frequency of PD-1 expressing T lymphocytes was decreased in both pSS and SSc. The frequency of IDO-expressing APCs, as well as intracellular IDO content in T cells was higher in pSS than in controls. Our investigation identified a number of differences in B7 costimulation between SSc and pSS patients which may play a role in the distinct pathogenesis and clinical features of these autoimmune disorders.
Literatur
1.
Zurück zum Zitat Harris NL, Ronchese F. The role of B7 costimulation in T-cell immunity. Immunol Cell Biol. 1999;77:304–11.CrossRefPubMed Harris NL, Ronchese F. The role of B7 costimulation in T-cell immunity. Immunol Cell Biol. 1999;77:304–11.CrossRefPubMed
2.
Zurück zum Zitat Gimmi CD, Freeman GJ, Gribben JG, et al. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci U S A. 1993;90:6586–90.CrossRefPubMedPubMedCentral Gimmi CD, Freeman GJ, Gribben JG, et al. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci U S A. 1993;90:6586–90.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Chambers CA, Kuhns MS, Egen JG, et al. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol. 2001;19:565–94.CrossRefPubMed Chambers CA, Kuhns MS, Egen JG, et al. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol. 2001;19:565–94.CrossRefPubMed
4.
Zurück zum Zitat Wang S, Bajorath J, Flies DB, et al. Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction. J Exp Med. 2003;197:1083–91.CrossRefPubMedPubMedCentral Wang S, Bajorath J, Flies DB, et al. Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction. J Exp Med. 2003;197:1083–91.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11:141–51.CrossRefPubMed Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11:141–51.CrossRefPubMed
6.
Zurück zum Zitat Coyle AJ, Lehar S, Lloyd C, et al. The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity. 2000;13:95–105.CrossRefPubMed Coyle AJ, Lehar S, Lloyd C, et al. The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity. 2000;13:95–105.CrossRefPubMed
7.
Zurück zum Zitat Wang S, Chen L. T lymphocyte co-signaling pathways of the B7-CD28 family. Cell Mol Immunol. 2004;1:37–42.PubMed Wang S, Chen L. T lymphocyte co-signaling pathways of the B7-CD28 family. Cell Mol Immunol. 2004;1:37–42.PubMed
8.
9.
Zurück zum Zitat Grohmann U, Orabona C, Fallarino F, et al. CTLA-4-Ig regulates tryphtophan catabolism in vivo. Nat Immunol. 2002;3:1097–101.CrossRefPubMed Grohmann U, Orabona C, Fallarino F, et al. CTLA-4-Ig regulates tryphtophan catabolism in vivo. Nat Immunol. 2002;3:1097–101.CrossRefPubMed
10.
Zurück zum Zitat Mándi Y, Vécsei L. The kynurenine system and immunoregulation. J Neural Transm (Vienna). 2012;119:197–209.CrossRef Mándi Y, Vécsei L. The kynurenine system and immunoregulation. J Neural Transm (Vienna). 2012;119:197–209.CrossRef
11.
Zurück zum Zitat Filippini P, Del Papa N, Sambataro D, et al. Emerging conception inhibitors of indoleamine 2,3-dioxygenase in rheumatic disease. Curr Med Chem. 2012;19:5381–593.CrossRefPubMed Filippini P, Del Papa N, Sambataro D, et al. Emerging conception inhibitors of indoleamine 2,3-dioxygenase in rheumatic disease. Curr Med Chem. 2012;19:5381–593.CrossRefPubMed
12.
Zurück zum Zitat Hansen A, Lipsky PE, Dörner T. New concepts in the pathogenesis of Sjögren syndrome: many questions, fewer answers. Curr Opin Rheumol. 2003;15:563–70.CrossRef Hansen A, Lipsky PE, Dörner T. New concepts in the pathogenesis of Sjögren syndrome: many questions, fewer answers. Curr Opin Rheumol. 2003;15:563–70.CrossRef
15.
Zurück zum Zitat de Paoli FV, Nielsen BD, Rasmussen F, et al. Abatacept induces clinical improvement in patients with severe systemic sclerosis. Scand J Rheumatol. 2014;43:342–5.CrossRefPubMed de Paoli FV, Nielsen BD, Rasmussen F, et al. Abatacept induces clinical improvement in patients with severe systemic sclerosis. Scand J Rheumatol. 2014;43:342–5.CrossRefPubMed
16.
Zurück zum Zitat Meiners PM, Vissink A, Kroese FG, et al. Abatacept treatment reduces disease activity in early primary Sjögren’s syndrome. Ann Rheum Dis. 2014;73:1393–6.CrossRefPubMed Meiners PM, Vissink A, Kroese FG, et al. Abatacept treatment reduces disease activity in early primary Sjögren’s syndrome. Ann Rheum Dis. 2014;73:1393–6.CrossRefPubMed
17.
Zurück zum Zitat Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554–8.CrossRefPubMedPubMedCentral Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554–8.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Shiboski SC, Shiboski CH, Criswell L, et al. American College of Rheumatology classification criteria for Sjögren’s syndrome: a data-driven expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res. 2012;64:475–87.CrossRef Shiboski SC, Shiboski CH, Criswell L, et al. American College of Rheumatology classification criteria for Sjögren’s syndrome: a data-driven expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res. 2012;64:475–87.CrossRef
19.
20.
Zurück zum Zitat van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum. 2013;65:2737–47.CrossRefPubMedPubMedCentral van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum. 2013;65:2737–47.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202–5.PubMed LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202–5.PubMed
23.
Zurück zum Zitat Rudd CE, Schneider H. Unifying concepts inCD28, ICOS and CTLA4 co-receptor signalling. Nat Rev Immunol. 2003;3:544–56.CrossRefPubMed Rudd CE, Schneider H. Unifying concepts inCD28, ICOS and CTLA4 co-receptor signalling. Nat Rev Immunol. 2003;3:544–56.CrossRefPubMed
24.
Zurück zum Zitat Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science. 1995;270:985–8.CrossRefPubMed Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science. 1995;270:985–8.CrossRefPubMed
25.
Zurück zum Zitat Odegard JM, Di Placido LD, Greenwald L, et al. ICOS controls effector function but not trafficking receptor expression of kidney-infiltrating effector T cells in murine lupus. J Immunol. 2009;182:4076–84.CrossRefPubMedPubMedCentral Odegard JM, Di Placido LD, Greenwald L, et al. ICOS controls effector function but not trafficking receptor expression of kidney-infiltrating effector T cells in murine lupus. J Immunol. 2009;182:4076–84.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Gong YZ, Nititham J, Taylor K, et al. Differentiation of follicular helper T cells by salivary gland epithelial cells in primary Sjögren’s syndrome. J Autoimmunity. 2014;51:57–66.CrossRef Gong YZ, Nititham J, Taylor K, et al. Differentiation of follicular helper T cells by salivary gland epithelial cells in primary Sjögren’s syndrome. J Autoimmunity. 2014;51:57–66.CrossRef
27.
Zurück zum Zitat Teichmann LL, Cullen JL, Kashgarian M, et al. Local triggering of the ICOS coreceptor by CD11c + myeloid cells drives organ inflammation in lupus. Immunity. 2015;42:552–65.CrossRefPubMedPubMedCentral Teichmann LL, Cullen JL, Kashgarian M, et al. Local triggering of the ICOS coreceptor by CD11c + myeloid cells drives organ inflammation in lupus. Immunity. 2015;42:552–65.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Chikuma S. Basics of PD-1 in self-tolerance, infection, and cancer immunity. Int J Clin Oncol. 2016;21:448–55.CrossRefPubMed Chikuma S. Basics of PD-1 in self-tolerance, infection, and cancer immunity. Int J Clin Oncol. 2016;21:448–55.CrossRefPubMed
30.
Zurück zum Zitat Williams RO. Exploitation of the IDO pathway in the therapy of rheumatoid arthritis. Int J Tryptophan Res. 2013;21:67–73.CrossRef Williams RO. Exploitation of the IDO pathway in the therapy of rheumatoid arthritis. Int J Tryptophan Res. 2013;21:67–73.CrossRef
31.
Zurück zum Zitat Furuzawa-Carballeda J, Hernández-Molina G, Lima G, et al. Peripheral regulatory cells immunophenotyping in primary Sjögren’s syndrome: a cross-sectional study. Arthritis Res Ther. 2013;15:R68.CrossRefPubMedPubMedCentral Furuzawa-Carballeda J, Hernández-Molina G, Lima G, et al. Peripheral regulatory cells immunophenotyping in primary Sjögren’s syndrome: a cross-sectional study. Arthritis Res Ther. 2013;15:R68.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Petrovaara M. RaitalaA, Uusitalo H, et al. Mechanisms dependent on tryptophan catabolism regulate immune responses in primary Sjögren’s syndrome. Clin Exp Immunol. 2005;142:155–61.CrossRef Petrovaara M. RaitalaA, Uusitalo H, et al. Mechanisms dependent on tryptophan catabolism regulate immune responses in primary Sjögren’s syndrome. Clin Exp Immunol. 2005;142:155–61.CrossRef
Metadaten
Titel
The role of B7 family costimulatory molecules and indoleamine 2,3-dioxygenase in primary Sjögren’s syndrome and systemic sclerosis
verfasst von
Nóra Legány
László Berta
László Kovács
Attila Balog
Gergely Toldi
Publikationsdatum
23.11.2016
Verlag
Springer US
Erschienen in
Immunologic Research / Ausgabe 3/2017
Print ISSN: 0257-277X
Elektronische ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-016-8880-0

Weitere Artikel der Ausgabe 3/2017

Immunologic Research 3/2017 Zur Ausgabe

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.